149 related articles for article (PubMed ID: 19226467)
1. Effects of the single nucleotide polymorphism at MDM2 309 on breast cancer patients with/without BRCA1/2 mutations.
Nechushtan H; Hamburger T; Mendelson S; Kadouri L; Sharon N; Pikarsky E; Peretz T
BMC Cancer; 2009 Feb; 9():60. PubMed ID: 19226467
[TBL] [Abstract][Full Text] [Related]
2. MDM2 SNP309 accelerates breast and ovarian carcinogenesis in BRCA1 and BRCA2 carriers of Jewish-Ashkenazi descent.
Yarden RI; Friedman E; Metsuyanim S; Olender T; Ben-Asher E; Papa MZ
Breast Cancer Res Treat; 2008 Oct; 111(3):497-504. PubMed ID: 18026875
[TBL] [Abstract][Full Text] [Related]
3. Influence of the MDM2 single nucleotide polymorphism SNP309 on tumour development in BRCA1 mutation carriers.
Copson ER; White HE; Blaydes JP; Robinson DO; Johnson PW; Eccles DM
BMC Cancer; 2006 Mar; 6():80. PubMed ID: 16563154
[TBL] [Abstract][Full Text] [Related]
4. Combined effects of single nucleotide polymorphisms TP53 R72P and MDM2 SNP309, and p53 expression on survival of breast cancer patients.
Schmidt MK; Tommiska J; Broeks A; van Leeuwen FE; Van't Veer LJ; Pharoah PD; Easton DF; Shah M; Humphreys M; Dörk T; Reincke SA; Fagerholm R; Blomqvist C; Nevanlinna H
Breast Cancer Res; 2009; 11(6):R89. PubMed ID: 20021639
[TBL] [Abstract][Full Text] [Related]
5. A single nucleotide polymorphism in the RAD51 gene modifies cancer risk in BRCA2 but not BRCA1 carriers.
Levy-Lahad E; Lahad A; Eisenberg S; Dagan E; Paperna T; Kasinetz L; Catane R; Kaufman B; Beller U; Renbaum P; Gershoni-Baruch R
Proc Natl Acad Sci U S A; 2001 Mar; 98(6):3232-6. PubMed ID: 11248061
[TBL] [Abstract][Full Text] [Related]
6. Genetic Predisposition to Breast Cancer Due to Mutations Other Than BRCA1 and BRCA2 Founder Alleles Among Ashkenazi Jewish Women.
Walsh T; Mandell JB; Norquist BM; Casadei S; Gulsuner S; Lee MK; King MC
JAMA Oncol; 2017 Dec; 3(12):1647-1653. PubMed ID: 28727877
[TBL] [Abstract][Full Text] [Related]
7. MDM2 SNP309 accelerates familial breast carcinogenesis independently of estrogen signaling.
Wasielewski M; Nagel JH; Brekelmans C; Klijn JG; van den Ouweland A; Meijers-Heijboer H; Schutte M
Breast Cancer Res Treat; 2007 Aug; 104(2):153-7. PubMed ID: 17080308
[TBL] [Abstract][Full Text] [Related]
8. MDM2 SNP309 is associated with high grade node positive breast tumours and is in linkage disequilibrium with a novel MDM2 intron 1 polymorphism.
Paulin FE; O'Neill M; McGregor G; Cassidy A; Ashfield A; Ali CW; Munro AJ; Baker L; Purdie CA; Lane DP; Thompson AM
BMC Cancer; 2008 Oct; 8():281. PubMed ID: 18828900
[TBL] [Abstract][Full Text] [Related]
9. Association of breast cancer outcome with status of p53 and MDM2 SNP309.
Boersma BJ; Howe TM; Goodman JE; Yfantis HG; Lee DH; Chanock SJ; Ambs S
J Natl Cancer Inst; 2006 Jul; 98(13):911-9. PubMed ID: 16818855
[TBL] [Abstract][Full Text] [Related]
10. A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment.
Robson ME; Chappuis PO; Satagopan J; Wong N; Boyd J; Goffin JR; Hudis C; Roberge D; Norton L; Bégin LR; Offit K; Foulkes WD
Breast Cancer Res; 2004; 6(1):R8-R17. PubMed ID: 14680495
[TBL] [Abstract][Full Text] [Related]
11. Functional variant of KLOTHO: a breast cancer risk modifier among BRCA1 mutation carriers of Ashkenazi origin.
Wolf I; Laitman Y; Rubinek T; Abramovitz L; Novikov I; Beeri R; Kuro-O M; Koeffler HP; Catane R; Freedman LS; Levy-Lahad E; Karlan BY; Friedman E; Kaufman B
Oncogene; 2010 Jan; 29(1):26-33. PubMed ID: 19802015
[TBL] [Abstract][Full Text] [Related]
12. The TP53 Arg72Pro and MDM2 309G>T polymorphisms are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers.
Sinilnikova OM; Antoniou AC; Simard J; Healey S; Léoné M; Sinnett D; Spurdle AB; Beesley J; Chen X; ; Greene MH; Loud JT; Lejbkowicz F; Rennert G; Dishon S; Andrulis IL; ; Domchek SM; Nathanson KL; Manoukian S; Radice P; Konstantopoulou I; Blanco I; Laborde AL; Durán M; Osorio A; Benitez J; Hamann U; Hogervorst FB; van Os TA; Gille HJ; ; Peock S; Cook M; Luccarini C; Evans DG; Lalloo F; Eeles R; Pichert G; Davidson R; Cole T; Cook J; Paterson J; Brewer C; ; Hughes DJ; Coupier I; Giraud S; Coulet F; Colas C; Soubrier F; Rouleau E; Bièche I; Lidereau R; Demange L; Nogues C; Lynch HT; ; Schmutzler RK; Versmold B; Engel C; Meindl A; Arnold N; Sutter C; Deissler H; Schaefer D; Froster UG; ; Aittomäki K; Nevanlinna H; McGuffog L; Easton DF; Chenevix-Trench G; Stoppa-Lyonnet D;
Br J Cancer; 2009 Oct; 101(8):1456-60. PubMed ID: 19707196
[TBL] [Abstract][Full Text] [Related]
13. Results based on 124 cases of breast cancer and 97 controls from Taiwan suggest that the single nucleotide polymorphism (SNP309) in the MDM2 gene promoter is associated with earlier onset and increased risk of breast cancer.
Sun YF; Leu JD; Chen SM; Lin IF; Lee YJ
BMC Cancer; 2009 Jan; 9():13. PubMed ID: 19144119
[TBL] [Abstract][Full Text] [Related]
14. The yield of full BRCA1/2 genotyping in Israeli high-risk breast/ovarian cancer patients who do not carry the predominant mutations.
Barnes-Kedar I; Bernstein-Molho R; Ginzach N; Hartmajer S; Shapira T; Magal N; Kalis ML; Peretz T; Shohat M; Basel-Salmon L; Friedman E; Bazak L; Goldberg Y
Breast Cancer Res Treat; 2018 Nov; 172(1):151-157. PubMed ID: 30014164
[TBL] [Abstract][Full Text] [Related]
15. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
[TBL] [Abstract][Full Text] [Related]
16. The significance of MDM2 SNP309 and p53 Arg72Pro in young women with breast cancer.
Lång A; Palmebäck Wegman P; Wingren S
Oncol Rep; 2009 Sep; 22(3):575-9. PubMed ID: 19639206
[TBL] [Abstract][Full Text] [Related]
17. Similar prevalence of founder BRCA1 and BRCA2 mutations among Ashkenazi and non-Ashkenazi men with breast cancer: evidence from 261 cases in Israel, 1976-1999.
Chodick G; Struewing JP; Ron E; Rutter JL; Iscovich J
Eur J Med Genet; 2008; 51(2):141-7. PubMed ID: 18158280
[TBL] [Abstract][Full Text] [Related]
18. Early onset breast cancer in Ashkenazi women carriers of founder BRCA1/2 mutations: beyond 10 years of follow-up.
Dagan E; Gershoni-Baruch R; Kurolap A; Fried G
Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 27726213
[TBL] [Abstract][Full Text] [Related]
19. Effect of the MDM2 promoter polymorphisms SNP309T>G and SNP285G>C on the risk of ovarian cancer in BRCA1 mutation carriers.
Bjørnslett M; Knappskog S; Lønning PE; Dørum A
BMC Cancer; 2012 Oct; 12():454. PubMed ID: 23039163
[TBL] [Abstract][Full Text] [Related]
20. MDM2 promoter SNP309 is associated with an increased susceptibility to chronic lymphocytic leukemia and correlates with MDM2 mRNA expression in Chinese patients with CLL.
Dong HJ; Fang C; Fan L; Zhu DX; Wang DM; Zhu HY; Zhuang Y; Miao KR; Liu P; Xu W; Li JY
Int J Cancer; 2012 May; 130(9):2054-61. PubMed ID: 21647873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
